Substantial doubt about the company's ability to continue as a going concern.
“As a result, we have concluded that there is substantial doubt about our ability to continue as a going concern within one year after the date the unaudited condensed consolidated financial statements included elsewhere in this Form 10-Q are issued.”View the 10-Q filed Nov 9, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
P3 Health Partners reported Q3 adjusted EBITDA of $21 million and raised full-year 2026 guidance to $90 million to $110 million, with a $100 million midpoint, while year-to-date adjusted EBITDA reached $101 million.
P3 Health Partners Inc. reported total operating revenue of 396,344 (in thousands), up 15%, and net income of 30,777 (in thousands) for the three months ended September 30, 2026.
P3 Health Partners Inc. registered up to 15,636,134 Class A common shares for selling-stockholder resale after warrant exercises. It receives no resale proceeds but could receive approximately $167.9 million from cash exercises.
